WE WANT Neurofibromatosis TO BE RECOGNIZED AS A CONDITION
i copied this from a site to let people know about NF but please still see your doctor for anything med treatment
THIS IS TO HELP GEY SUPPORT 24/7 FOR PEOPLE THAT NEED TO TALK OR WORRIED GET GROUPS GOING AND HOILDAYS FOR FAMILY THAT HAVE BEEN THOUGH A LOT AND GET FUNDING LIKE ALL THE OTHER CONDITIONS THAT MAKE US ILL KIDS FIGHTING LIFE
SORRY my spelling not that good
Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known asvon Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign and may cause serious damage by compressing nerves and other tissues. The disorder can affect many neural crest cell-derived nerve tissues (e.g., Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytesalso function abnormally in this disease, resulting in disordered skin pigmentation and café au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.
Neurofibromatosis is an autosomal dominant disorder, which means only one copy of the affected gene is needed for the disorder to develop. Therefore, if only one parent has neurofibromatosis, his or her children have a 50% chance of developing the condition as well. The severity in affected individuals can vary; this may be due to variable expressivity. Approximately half of cases are due to de novo mutations and no other affected family members are seen. It affects males and females equally.
- 1 Classification
- 2 Signs and symptoms
- 3 Diagnosis
- 4 Genetics
- 5 Pathophysiology
- 6 Treatment
- 7 History
- 8 Notable cases
- 9 Research
- 10 References
- 11 External links
Classification[edit source | edit]
Neurofibromatosis type 1 (NF 1)[edit source | edit]
Neurofibromatosis type 1 (also known as "von Recklinghausen disease") is the most common form of NF, accounting for up to 90% of all cases. NF 1 has a disorder frequency of 1 in 4,000, making it more common than neurofibromatosis type 2, with a frequency of 1 in 45,000 people. It occurs following the mutation of neurofibromin 1 on chromosome 17q11.2; the large size of the NF1 gene (286kbp) and presence of many homologous regions may predispose it to mutations. 100,000 Americans have neurofibromatosis. Neurofibromin is a tumor suppressor gene whose function is to inhibit the p21 ras oncoprotein. In absence of this tumor suppressor's inhibitory control on the ras oncoprotein, cellular proliferation is erratic and uncontrolled, resulting in unbalanced cellular proliferation and tumor development. The diagnosis of NF1 is made if any two of the following nine criteria are met:
- Two or more neurofibromas on or under the skin, or one plexiform neurofibroma (a large cluster of tumors involving multiple nerves); neurofibromas are the subcutaneous bumps characteristic of the disease, and increase in number with age.
- Freckling of the groin or the axilla (arm pit).
- Café au lait spots (pigmented, light brown macules located on nerves, with smooth edged, "coast of California" birthmarks). Six or more measuring 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in postpubertal individuals.
- Skeletal abnormalities, such as sphenoid dysplasia or thinning of the cortex of the long bones of the body (i.e. bones of the leg, potentially resulting in bowing of the legs)
- Lisch nodules (hamartomas of iris), freckling in the iris
- Tumors on the optic nerve, also known as an optic glioma
- A first-degree relative (parent, sibling, or child) with NF-1 according to the preceding criteria.
Other features that may be seen in individuals with NF-1 are:
- Scoliosis with or without kyphosis
- Macrocephaly in 30–50% of the pediatric population without any hydrocephalus
- Epilepsy (seizures)
- Juvenile posterior lenticular opacity
- Learning disabilities: Children with NF1 may have impaired cognitive skills and/or language difficulties. One common learning disability among children with NF1 is Attention Deficit/Hyperactivity Disorder (ADHD).
- Larger than average head size: Children with NF1 often have a larger head and brain size than average.
Neurofibromatosis type 2 (NF 2)[edit source | edit]
Neurofibromatosis type 2 (also called "central neurofibromatosis") is the result of mutation of the protein merlin (also known as "Neurofibromin 2" or "schwannomin") in chromosome 22q12. It accounts for only 10% of all cases of NF, and its frequency is lower than NF1. It is also caused by a mutation in a tumor suppressor gene NF2 (whose gene product is schwannomin or merlin). The normal function of merlin is not well understood. The disorder manifests in the following fashion:
- bilateral acoustic neuromas (tumors of the vestibulocochlear nerve or cranial nerve 8 (CN VIII) also known as schwannoma), often leading to hearing loss. In fact, the hallmark of NF 2 is hearing loss due to acoustic neuromas around the age of twenty.
- The tumors may cause:
- balance problems, and peripheral vertigo often due to schwannoma and involvement of the inner ear
- facial weakness/paralysis due to involvement or compression of the facial nerve (cranial nerve 7 or CN VII)
- patients with NF2 may also develop other brain tumors, as well as spinal tumors.
- deafness and tinnitus
Schwannomatosis[edit source | edit]
Schwannomatosis — mutation in both chromosomes 17 and 22
- Multiple schwannomas occur.
- The schwannomas develop on cranial, spinal and peripheral nerves.
- Chronic pain, and sometimes numbness, tingling and weakness
- About 1/3 of patients have segmental schwannomatosis, which means the schwannomas are limited to a single part of the body, such as an arm, a leg or the spine.
- Unlike the other forms of NF, the schwannomas do not develop on vestibular nerves, and as a result, no loss of hearing is associated with schwannomatosis.
- Patients with schwannomatosis do not have learning disabilities related to the disorder.
One must keep in mind, however, that neurofibromatosis can occur in or affect any of the organ systems, whether that entails simply compressing them (from tumor growth) or in fact altering the organs in some fundamental way. This disparity in the disorder is one of many factors that makes it difficult to diagnose, and eventually find a prognosis for.
Other variants[edit source | edit]
- Neurofibromatosis type 3A: A rare genetic disorder characterized by areas of increased and decreased skin pigmentation and the development of many non-cancerous nerve and skin tumors some of which may eventually become malignant. The skin tumors tend to develop characteristically on the palms of the hands
- Neurofibromatosis type 4 of Riccardi: A rare genetic disorder characterized by areas of increased and decreased skin pigmentation and the development of many non-cancerous nerve and skin tumors some of which may eventually become malignant.
- Neurofibromatosis type 5
Related disorders[edit source | edit]
Neurofibromatosis is considered a member of the neurocutaneous syndromes (phakomatoses). In addition to the types of neurofibromatosis, the phakomatoses also include tuberous sclerosis, Sturge-Weber syndrome and von Hippel-Lindau disease. This grouping is an artifact of an earlier time in medicine, before the distinct genetic basis of each of these diseases was understood.
Signs and symptoms[edit source | edit]
Patients with neurofibromatosis can be affected in many different ways. Morbidity is often a result of plexiform neuromas, optic gliomas, or acoustic neuromas, but mortality can also be associated with malignant transformation of the neuromas, such as neurofibrosarcomas (often there is a malignant transformation in less than 3% of the cases of NF1). There is a high incidence of learning disabilities or cognitive deficit in patients with NF, particularly NF-1, however severe retardation is not part of the syndrome. Because of the tumor generating nature of the disorder and its involvement of the nervous system and also because of early onset macrocephaly in the pediatric population, there is often an increased chance of development of epilepsy in those affected. Neurofibromatosis also increases the risk of leukemiaparticularly in children; Children with NF-1 have 200 to 500 times the normal risk of developing leukemia compared to the general population. Since the tumors grow where there are nerves, they can also grow in areas that are visible, causing considerable social suffering for those affected. The tumors can also grow in places that can cause other medical issues that may require them to be removed for the patient's safety. Affected individuals may need multiple surgeries (such as reduction surgery, or Gamma knife surgery), depending on where the tumors are located. For instance, those affected with NF 2 might benefit from a surgical decompression of the vestibular tumors to prevent deafness.
Diagnosis[edit source | edit]
Prenatal testing[edit source | edit]
Embryo[edit source | edit]
"PGD has about 95–98% accuracy but requires that the partner with NF2 have a recognizable genetic mutation, which is only the case for about 60% of people with a clinical diagnosis of NF2. Having the initial genetic testing to determine if the mutation is recognizable takes approximately 6 months, and then preparing the probes for the PDG testing takes approximately another 6 months."
Fetus[edit source | edit]
- To detect Neurofibromatosis type I.
- To detect Neurofibromatosis type II with 95% accuracy.
- Can not be used to detect Schwannomatosis, because the gene for it has not yet been identified.
Genetics[edit source | edit]
Neurofibromatosis type 1 is caused by mutation on chromosome 17q11.2, the gene product beingneurofibromin 1 (a regulator of the GTPase activating enzyme (GAP)). Neurofibromatosis type 2 is due to mutation on chromosome 22q, the gene product is merlin, a cytoskeletal protein.
Both NF-1 and NF-2 are autosomal dominant disorders, meaning only one copy of the mutated gene need be inherited to pass the disorder. A child of a parent with NF-1 or NF-2 and an unaffected parent will have a 50–100% chance of inheriting the disorder, depending on whether the affected parent is heterozygous (Aa) or homozygous (AA) for the trait ("A" depicts the affected dominant allele, while "a" depics the recessive allele).
Complicating the question of heritability is the distinction between genotype and phenotype, that is, between the genetics and the actual manifestation of the disorder. In the case of NF1, no clear links between genotype and phenotype have been found, and the severity and the specific nature of the symptoms may vary widely among family members with the disorder. This is a good example of the phenomenon of variable expressivity: the differing severities of disease in different individuals with the same genotype. In the case of NF-2, however, manifestations are similar among family members; a strong genotype-phenotype correlation is believed to exist. Both NF-1 and NF-2 can also appear to be spontaneous de novo mutations, with no family history. These cases account for about one half of neurofibromatosis cases.
Similar to polydactyly, NF is also an autosomally dominant mutation, that is not prevalent in the society. Neurofibromatosis-1 is found in approximately 1 in 2,500–3,000 live births (carrier incidence 0.0004, gene frequency 0.0002) and is more common than NF-2.
Pathophysiology[edit source | edit]
The gene affected in NF-1, is located on the long arm of the chromosome 17 (q11.2). It encodes for a protein called neurofibromin, otherwise known as a "tumor suppressor" protein. This protein is a negative regulator of the Ras kinase pathway (p21 oncoprotein).Neurofibromatosis alters or weakens this protein (due to deletion, missense mutation, or nonsense mutations,) allowing rapid, radical growth of cells all over the body, especially around the nervous system. The essential problem is the inability to inactivate GTP due to a defective GTP-ase (neurofibromin). This leads to the common symptoms for neurofibromatosis — clumpings of the tumors, called neurofibromas and schwannomas. Less is known about the NF-2 linked gene and its product, merlin. However, it is on the long arm of the chromosome 22q(11.1-13.1) and codes for the protein.
Treatment[edit source | edit]
Because there is no cure for the condition itself, the only therapy for patients with neurofibromatosis is a program of treatment by a team of specialists to manage symptoms or complications. Surgery may be needed when the tumors compress organs or other structures. Less than 10% of people with neurofibromatosis develop cancerous growths; in these cases, chemotherapy may be successful.
For families with NF, genetic screening and counselling is available.
History[edit source | edit]
Neurofibromatosis (or von Recklinghausen disease) was first described in 1882 by the German pathologist, Friedrich Daniel von Recklinghausen. As a young scientist, Recklinghausen was the student of the renowned Rudolf Virchow in Berlin. Recklinghausen was successful in generating some of the most descriptive medical observations of his time, making him the first person to describe and coin the term "hemachromatosis" (Hämochromatose, Tageblatt der Naturforschenden Versammlung). Recklinghausen is now known for his contributions to staining methods, and most importantly for his important paper on neurofibromatosis published in 1881, to honor Rudolf Virchow’s 25 year jubilee, in which he describes neurofibromatosis. Today he is recognized as a distinguished histopathologist, and a great scientist, he lends his name to the syndrome, which he himself elucidated.
Notable cases[edit source | edit]
In May 2011, a case was reported in the United Kingdom in which a 15-month-old child who turned out to have Neurofibromatosis type I was misdiagnosed as being abused under the assumption that the mother had Münchausen syndrome by proxy, because the child gained weight while in the hospital and lost weight while at home. The child was placed in foster care for 6 months and then returned to his parents after he was correctly diagnosed.
In January 2008, 32-year-old Huang Chuncai of China underwent a second operation to remove another 4.5 kg (9.9 lb) of tumor from his face. A previous operation removed 15 kg (33 lb) from what was originally a 23 kg (55.7 lb) tumor.
In March 2007, the treatment of 30-year-old neurofibromatosis patient Pascal Coler of France ended after he had received what his doctors call the world's first successful full face transplant.
In November 2006, there was an hour-long documentary on the British television network Channel 4 about Facing the World, an organization that helps children with severe facial disfigurements in developing countries. One of the children featured on the documentary was Arianto, an Indonesian boy who suffered from a severe form of neurofibroma resulting in hemifacial giganticism.
Also in that year, another documentary on BBC2 (edge of life) featured a neurofibromatosis case. On that documentary was a young teenager, Amit Ghose, who had decided for himself to have corrective surgery at the age of 14. In this case, the neurofibroma occurred on the face, resulting in the loss of sight in one eye and having to have it removed. This was a case of NF-2, resulting in the disfigurement of the one side of the face, while leaving the other side completely normal.
In 2012, surgeons removed a 200-pound tumor caused by neurofibromatosis from a Vietnamese man's leg; the tumor weighed twice as much as the rest of his body.
Joseph Merrick, the Elephant Man, was once considered to have been affected with neurofibromatosis type I. It is likely, however, that Merrick suffered from the very rare Proteus syndrome. This has produced a common misconception that neurofibromatosis and the "Elephant Man disease" are one and the same.
Research[edit source | edit]
References[edit source | edit]
|Wikinews has related news: Interview with Reggie Bibbs on his life with neurofibromatosis|
- Raphael Rubin, David S. Strayer (2008 Baltimore). Rubin's Pathology: Clinicopathologic Foundation of Medicine (5 ed.). Wolters Kluwer Health: Lippincot Williams & Wilkins. pp. 201–3. ISBN 978-0-7817-9516-6.
- Conrad Fischer, Farshad Bagheri, Rajpal Manchandani, Richard Pinsker, Sudheer Chauhan, Parenkumar Patel, Mohammad Maruf, Dhaval Satani, Kaushik Doshi, Ayaz Alwani, Naveen Pathak, Craigh Thurm, Mohammad Babury, Mahendra C. Patel, Arthur Shalanov, Samir Sarkar, Sabiha Raouf, Jebun Nahar, Prakashkumar Patel (2010). Master the Board USMLE Step 2 CK. KAPLAN Medical. p. 287. ISBN 978-1-60714-653-7.
- John Barone (2008). USMLE Step 1 Lecture Notes: Pathology. KAPLAN Inc. p. 57.
- William D James, Raj D Sheth, Nazanin Saedi (Jul 20, 2009). Cafe Au Lait Spots. eMedicine from WebMD. Retrieved 13 December 2010.
- Steen RG, Taylor JS, Langston JW, et al. (May 2001). "Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities". AJNR Am J Neuroradiol 22 (5): 810–7.PMID 11337320.
- Mayo Clinic. (2013). Neurofibromatosis: symptoms. Mayoclinic.com Retrieved 13 June 2013.
- Mayo Clinic. (2013). Neurofibromatosis: symptoms. www.mayoclinic.com Retrieved 13 June 2013.
- Goutagny, S; Kalamarides, M (September 2010). "Meningiomas and neurofibromatosis.". Journal of neuro-oncology 99 (3): 341–7.doi:10.1007/s11060-010-0339-x. PMID 20714782.
- Health Grades Inc.(2013). "Neurofibfomatosis type 3A". Retrieved 12 June 2013.
- Health Grades Inc. (2013). Neurofibromatosis, type 4, of Riccardi . Retrieved 12 June 2013.
- Hayashi M, Chernov M, Tamura N, Yomo S, Ochiai T, Nagai M, Tamura M, Izawa M, Muragaki Y, Iseki H, Okada Y, Takakura K. (December 2010). "Gamma Knife surgery for abducent nerve schwannoma. Report of 4 cases". Journal of neurosurgery 113: 136–43.doi:10.3171/2010.8.GKS10947. PMID 21121795.